Mumbai: Once bitten twice shy? Not in the case of Venkat Jasti, chairman and CEO of Suven Life Sciences, who is gearing up to conduct Phase-3 clinical trials of a potential therapy against Alzheimer's disease despite its partial failure in Phase-2 study.